Logo image of EMEIS.PA

EMEIS SA (EMEIS.PA) Stock Fundamental Analysis

EPA:EMEIS - Euronext Paris - Matif - FR001400NLM4 - Common Stock - Currency: EUR

10.85  +0.34 (+3.24%)

Fundamental Rating

1

Overall EMEIS gets a fundamental rating of 1 out of 10. We evaluated EMEIS against 25 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of EMEIS have multiple concerns. EMEIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year EMEIS has reported negative net income.
In the past year EMEIS had a positive cash flow from operations.
In multiple years EMEIS reported negative net income over the last 5 years.
EMEIS had a positive operating cash flow in each of the past 5 years.
EMEIS.PA Yearly Net Income VS EBIT VS OCF VS FCFEMEIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

EMEIS's Return On Assets of -3.07% is on the low side compared to the rest of the industry. EMEIS is outperformed by 88.00% of its industry peers.
EMEIS has a Return On Equity of -23.89%. This is amonst the worse of the industry: EMEIS underperforms 88.00% of its industry peers.
The Return On Invested Capital of EMEIS (0.03%) is worse than 84.00% of its industry peers.
Industry RankSector Rank
ROA -3.07%
ROE -23.89%
ROIC 0.03%
ROA(3y)-7.04%
ROA(5y)-3.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EMEIS.PA Yearly ROA, ROE, ROICEMEIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150 200 250

1.3 Margins

Looking at the Operating Margin, with a value of 0.08%, EMEIS is doing worse than 84.00% of the companies in the same industry.
EMEIS's Operating Margin has declined in the last couple of years.
EMEIS does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 0.08%
PM (TTM) N/A
GM N/A
OM growth 3Y-79.31%
OM growth 5Y-64.56%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EMEIS.PA Yearly Profit, Operating, Gross MarginsEMEIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

0

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EMEIS is destroying value.
EMEIS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EMEIS has been reduced compared to 5 years ago.
The debt/assets ratio for EMEIS is higher compared to a year ago.
EMEIS.PA Yearly Shares OutstandingEMEIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
EMEIS.PA Yearly Total Debt VS Total AssetsEMEIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of 0.60, we must say that EMEIS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.60, EMEIS is doing worse than 76.00% of the companies in the same industry.
EMEIS has a debt to FCF ratio of 51.23. This is a negative value and a sign of low solvency as EMEIS would need 51.23 years to pay back of all of its debts.
EMEIS has a Debt to FCF ratio of 51.23. This is amonst the worse of the industry: EMEIS underperforms 88.00% of its industry peers.
EMEIS has a Debt/Equity ratio of 4.80. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 4.80, EMEIS is not doing good in the industry: 84.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 4.8
Debt/FCF 51.23
Altman-Z 0.6
ROIC/WACC0.01
WACC4.78%
EMEIS.PA Yearly LT Debt VS Equity VS FCFEMEIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

EMEIS has a Current Ratio of 0.62. This is a bad value and indicates that EMEIS is not financially healthy enough and could expect problems in meeting its short term obligations.
EMEIS has a worse Current ratio (0.62) than 80.00% of its industry peers.
A Quick Ratio of 0.62 indicates that EMEIS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.62, EMEIS is doing worse than 68.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.62
EMEIS.PA Yearly Current Assets VS Current LiabilitesEMEIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

4

3. Growth

3.1 Past

The earnings per share for EMEIS have decreased strongly by -142.36% in the last year.
Looking at the last year, EMEIS shows a quite strong growth in Revenue. The Revenue has grown by 8.43% in the last year.
The Revenue has been growing by 8.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-142.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.25%
Revenue 1Y (TTM)8.43%
Revenue growth 3Y9.45%
Revenue growth 5Y8.55%
Sales Q2Q%7.73%

3.2 Future

Based on estimates for the next years, EMEIS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.91% on average per year.
The Revenue is expected to grow by 2.70% on average over the next years.
EPS Next Y61.81%
EPS Next 2Y28.88%
EPS Next 3Y29.56%
EPS Next 5Y17.91%
Revenue Next Year5.29%
Revenue Next 2Y5.18%
Revenue Next 3Y5.22%
Revenue Next 5Y2.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EMEIS.PA Yearly Revenue VS EstimatesEMEIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
EMEIS.PA Yearly EPS VS EstimatesEMEIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 100 -100 200

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EMEIS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EMEIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EMEIS.PA Price Earnings VS Forward Price EarningsEMEIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, EMEIS is valued a bit cheaper than 68.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.04
EV/EBITDA N/A
EMEIS.PA Per share dataEMEIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

EMEIS's earnings are expected to grow with 29.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.88%
EPS Next 3Y29.56%

0

5. Dividend

5.1 Amount

No dividends for EMEIS!.
Industry RankSector Rank
Dividend Yield N/A

EMEIS SA

EPA:EMEIS (7/25/2025, 11:53:57 AM)

10.85

+0.34 (+3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-13 2025-05-13
Earnings (Next)07-24 2025-07-24
Inst Owners55.54%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.75B
Analysts75.38
Price Target12.34 (13.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF 10.04
P/OCF 3.71
P/B 1.02
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)1.08
FCFY9.96%
OCF(TTM)2.92
OCFY26.95%
SpS34.91
BVpS10.68
TBVpS-7.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.07%
ROE -23.89%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.03%
ROICexgc 0.04%
OM 0.08%
PM (TTM) N/A
GM N/A
FCFM 3.1%
ROA(3y)-7.04%
ROA(5y)-3.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-77.23%
ROICexcg growth 5Y-61.49%
ROICexc growth 3Y-76.08%
ROICexc growth 5Y-60.94%
OM growth 3Y-79.31%
OM growth 5Y-64.56%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 4.8
Debt/FCF 51.23
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.28%
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.62
Altman-Z 0.6
F-Score4
WACC4.78%
ROIC/WACC0.01
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.82%
Cap/Sales(5y)13.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-142.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.25%
EPS Next Y61.81%
EPS Next 2Y28.88%
EPS Next 3Y29.56%
EPS Next 5Y17.91%
Revenue 1Y (TTM)8.43%
Revenue growth 3Y9.45%
Revenue growth 5Y8.55%
Sales Q2Q%7.73%
Revenue Next Year5.29%
Revenue Next 2Y5.18%
Revenue Next 3Y5.22%
Revenue Next 5Y2.7%
EBIT growth 1Y103.51%
EBIT growth 3Y-77.35%
EBIT growth 5Y-61.53%
EBIT Next Year10863.7%
EBIT Next 3Y422.27%
EBIT Next 5Y253.99%
FCF growth 1Y293.3%
FCF growth 3YN/A
FCF growth 5Y14.58%
OCF growth 1Y28.92%
OCF growth 3Y-14.44%
OCF growth 5Y-10.16%